Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial

• Published in: Journal of psychopharmacology (Oxford) Vol. 28; no. 11; p. 1088
• Main Authors: Chagas, Marcos Hortes N, Zuardi, Antonio W, Tumas, Vitor, Pena-Pereira, Márcio Alexandre, Sobreira, Emmanuelle T, Bergamaschi, Mateus M, dos Santos, Antonio Carlos, Teixeira, Antonio Lucio, Hallak, Jaime E C, Crippa, José Alexandre S
• Format: Journal Article
• Language: English
• Published: United States 01.11.2014
• Subjects: Aged; Aged, 80 and over; Aspartic Acid - analogs & derivatives; Aspartic Acid - metabolism; Brain-Derived Neurotrophic Factor - blood; Cannabidiol - therapeutic use; Creatine - metabolism; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents - blood; Neuroprotective Agents - therapeutic use; Parkinson Disease - drug therapy; Proton Magnetic Resonance Spectroscopy; Putamen - metabolism; Quality of Life; Severity of Illness Index; Treatment Outcome; cannabidiol; cannabis; treatment; Parkinson’s disease

Parkinson's disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons. Although no neuroprotective treatments for PD have been found to date, the endocannabinoid system has emerged as a promising target. From a sample of 119 patients consecutively ev...